Bicara Therapeutics (NASDAQ:BCAX) Stock Gets Price Target Trim from HC Wainwright

Bicara Therapeutics (NASDAQ:BCAX) had its target price reduced by research analysts at HC Wainwright from $42.00 to $36.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price objective indicates a potential upside of 253.63% from the company’s current price.

BCAX has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Thursday, September 10th. Benchmark reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, October 29th. HSBC lowered Bicara Therapeutics to an “equal weight” rating in a research report on Tuesday, September 22nd. Morgan Stanley reduced their price target on Bicara Therapeutics from $41.00 to $30.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Citigroup restated a “market outperform” rating on shares of Bicara Therapeutics in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $30.33.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $10.18 on Wednesday. The firm’s fifty day simple moving average is $17.63 and its 200 day simple moving average is $20.88. Bicara Therapeutics has a twelve month low of $7.87 and a twelve month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.22). Sell-side analysts anticipate that Bicara Therapeutics will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In other Bicara Therapeutics news, CEO Ryan Cohlhepp sold 17,500 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the transaction, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. This represents a 8.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by corporate insiders.

Institutional Trading of Bicara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BCAX. BlackRock Inc. acquired a new position in shares of Bicara Therapeutics in the second quarter worth about $114,250,000. Jupiter Topco LLC purchased a new stake in Bicara Therapeutics during the 2nd quarter worth approximately $93,957,000. Janus Henderson Group PLC increased its holdings in Bicara Therapeutics by 26.2% during the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after purchasing an additional 692,933 shares during the last quarter. Siren L.L.C. increased its holdings in Bicara Therapeutics by 11.2% during the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after purchasing an additional 586,001 shares during the last quarter. Finally, Palo Alto Investors LP acquired a new position in shares of Bicara Therapeutics in the 2nd quarter valued at approximately $16,341,614.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.